Last reviewed · How we verify

H5N1 pandemic influenza vaccine

Seqirus · Phase 2 active Biologic

H5N1 pandemic influenza vaccine is a Biologic drug developed by Seqirus. It is currently in Phase 2 development.

At a glance

Generic nameH5N1 pandemic influenza vaccine
SponsorSeqirus
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about H5N1 pandemic influenza vaccine

What is H5N1 pandemic influenza vaccine?

H5N1 pandemic influenza vaccine is a Biologic drug developed by Seqirus.

Who makes H5N1 pandemic influenza vaccine?

H5N1 pandemic influenza vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What development phase is H5N1 pandemic influenza vaccine in?

H5N1 pandemic influenza vaccine is in Phase 2.

Related